Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

The frequency of joint bleeds and orthopaedic joint scores were evaluated in 121 patients with severe haemophilia who had started prophylactic treatment with clotting factor concentrates at least once weekly before the age of 10. 75 of the patients started before the age of 3, 31 at the age of 3–5 and 15 at the age of 6–9. Each subgroup was evaluated separately. In addition, a regimen of one infusion weekly was compared with that of two (haemophilia B) or three (haemophilia A) infusions weekly in each patient.

[1]  R. Ljung,et al.  Port‐A‐Cath usage in children with haemophilia: experience of 53 cases , 1998, Acta paediatrica.

[2]  J. Avorn,et al.  Prophylactic Use of Factor VIII: an Economic Evaluation , 1998, Thrombosis and Haemostasis.

[3]  E. Berntorp,et al.  Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  J. Lusher.  Prophylaxis in Children with Hemophilia: Is it the Optimal Treatment? , 1997, Thrombosis and Haemostasis.

[5]  H. Pettersson,et al.  Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.

[6]  W. Schramm,et al.  Socioeconomic impact of haemophilia care: results of a pilot study , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  S. Teutsch,et al.  Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. , 1996, The Journal of pediatrics.

[8]  E. Berntorp,et al.  Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  K. Khair,et al.  The impact of prophylactic treatment on children with severe haemophilia , 1996, British journal of haematology.

[10]  E. Berntorp.  Methods of haemophilia care delivery: regular prophylaxis versus episodic treatment , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[12]  M. Manco‐Johnson,et al.  Results of secondary prophylaxis in children with severe hemophilia , 1994, American journal of hematology.

[13]  R. Talamini,et al.  Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. , 1994, Seminars in hematology.

[14]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[15]  M. Blombäck,et al.  Prophylaxis with factor concentrates in preventing hemophilic arthropathy. , 1991, The American journal of pediatric hematology/oncology.

[16]  S. Rosén.  Assay of factor VIII:C with a chromogenic substrate. , 2009, Scandinavian journal of haematology. Supplementum.

[17]  Å. Ahlberg.  Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. , 1965, Acta orthopaedica Scandinavica. Supplementum.

[18]  G. Kahaly.  The Socioeconomic Impact , 2022 .